RxDoctor Payments Data

Shawnna Nye

Family · Fulton, NYNPI 1588392930

Payments from drug & device makers

$2,276in general payments, 2019–2025

Across 120 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$411
  • AbbVie$363
  • Novo Nordisk$293
  • AstraZeneca$290
  • Lilly USA, LLC$215
  • Exact Sciences$128
  • plus $575 from 12 others

What the payments were for

  • Food & beverage$2,276100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,276 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$10,289
Medicare patients
28
Services billed
157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$32,749
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$32,022
JardianceEmpagliflozin16$24,628
XareltoRivaroxaban16$19,615
TrulicityDulaglutide18$16,808
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$16,658
EliquisApixaban11$11,983
FarxigaDapagliflozin Propanediol11$11,921
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$10,790
TradjentaLinagliptin13$6,771
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,273
Venlafaxine Hcl ErVenlafaxine Hcl20$2,784
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,307
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,245
Atorvastatin Calcium130$1,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$293$32,74927 claims
GSKTrelegy Ellipta$411$32,02242 claims
Boehringer IngelheimJardiance, Tradjenta$40$31,39929 claims
AstraZenecaBreztri Aerosphere, Farxiga$290$28,57936 claims
Lilly USA, LLCTrulicity$215$16,80818 claims
PfizerEliquis$14$11,98311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in Fulton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →